CNR1 and obesity due to melanocortin 4 receptor deficiency: In kidney disease, JD5037 has been shown to improve diabetic nephropathy, by improving podocyte function and led to the production of a hybrid/third-generation CB1 antagonist, MRI-1867, which has been shown to improve obesity-induced CKD [54,77].